Dat	te:2023/03	3/17	
Υοι	ur Name: Jin J	iang	
Ma	nuscript Title: Cyclin	O promotes lung cance	er progression and cetuximab resistance via cell cycle
reg	gulation and CDK13 inte	raction	
Ma	nuscript number (if known)	):	
rela par to 1	ated to the content of your ties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.
The			nips/activities/interests as they relate to the <u>current</u>
to t	•	ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.
	tem #1 below, report all su time frame for disclosure i	s the past 36 months.  Name all entities with	ed in this manuscript without time limit. For all other items,  Specifications/Comments
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initia	al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone	
	_		
	processing charges, etc.)  No time limit for this item.		
	processing charges, etc.)	Time frame: pas	st 36 months
	No time limit for this item.  Grants or contracts from any entity (if not indicated	Time frame: pas	st 36 months
	processing charges, etc.) No time limit for this item.  Grants or contracts from	•	st 36 months
	Processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	XNone	st 36 months

Consulting fees

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the fo	llowing box:
	None		

Da	ite:2023/03	3/17	
Yo	ur Name: Wer	nhao Yu	
M	anuscript Title: Cyclin	O promotes lung cance	er progression and cetuximab resistance via cell cycle
	gulation and $\overline{CDK13}$ inte		
M	anuscript number (if known)	):	
rel pa to rel Th <u>ma</u>	lated to the content of your rties whose interests may be transparency and does not lationship/activity/interest, e following questions apply anuscript only.  e author's relationships/act	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d to the author's relationsh ivities/interests should be	Ill relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment is. If you are in doubt about whether to list a lo so.  Inips/activities/interests as they relate to the current  a defined broadly. For example, if your manuscript pertains it all relationships with manufacturers of antihypertensive
In	edication, even if that medic item #1 below, report all su e time frame for disclosure i	pport for the work report	ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
L	All support for the present manuscript (e.g., funding, provision of study materials,	XNone	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
<u> </u>	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		
)	Royalties or licenses	X None	
,			
	Royalties of licenses	XNone	

Consulting fees

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
			,
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
Г	•		
	None		

Da	te:2023/03	3/17	
Yo	ur Name: Tao	Fang	
Ma	nuscript Title: Cyclin	O promotes lung cance	er progression and cetuximab resistance via cell cycle
	gulation and CDK13 inte		
Ma	nuscript number (if known	):	
rela par to	ated to the content of your ries whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Ill relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment is. If you are in doubt about whether to list a
The		•	nips/activities/interests as they relate to the current
to		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.
	tem #1 below, report all su time frame for disclosure i	s the past 36 months.	ed in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initia	al planning of the work
	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials, medical writing, article		
	provision of study materials,		
	provision of study materials, medical writing, article processing charges, etc.)	Time frame: pas	st 36 months
2	provision of study materials, medical writing, article processing charges, etc.)	Time frame: pas	st 36 months
-	provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated		st 36 months
2	provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	XNone	st 36 months

Consulting fees

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	XNone	
13	financial interests		
	illialiciai liiterests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
	None		
1			

Da	te:2023/03	3/17		
Yo	ur Name:Yon	gmeng Li		
Ma	nuscript Title: Cyclin	O promotes lung cance	er progression and cetuximab resistance via cell cyc	le
	gulation and CDK13 inte			
Ma	nuscript number (if known)	):		
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply inuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertain e all relationships with manufacturers of antihypertensive the manuscript.	
	item #1 below, report all su e time frame for disclosure i	•	ed in this manuscript without time limit. For all other iter	ns,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initial	al planning of the work	
L	All support for the present	XNone		
	manuscript (e.g., funding, provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: pas	t 36 months	
<u> </u>	Grants or contracts from	XNone		
	any entity (if not indicated			
)	in item #1 above). Royalties or licenses	V None		
,	Noyalties of ficefises	XNone		

Consulting fees

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
	<b>3</b>			
8	Patents planned, issued or	X None		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			_
	writing, gifts or other			
13	services Other financial or non-	X None		
13	financial interests			
	illialiciai liitelests			
Ple	ease summarize the above o	onflict of interest in the fo	llowing box:	
	None			

Da	te:2023/03	3/1/	
Yo	ur Name: Jing	hui Liang	
Ma	nuscript Title: Cyclin	O promotes lung cance	er progression and cetuximab resistance via cell cycle
	gulation and CDK13 inte		
Ma	nuscript number (if known)	):	
rel par to rel The ma	ated to the content of your ries whose interests may be transparency and does not ationship/activity/interest, ationship questions apply nuscript only.	manuscript. "Related" mee affected by the content necessarily indicate a bias it is preferable that you do to the author's relationshivities/interests should be ension, you should declare	dips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
In i	tem #1 below, report all su	pport for the work report	ed in this manuscript without time limit. For all other items
	tem #1 below, report all su time frame for disclosure i	Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		Name all entities with whom you have this relationship or indicate	Specifications/Comments
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work
the .	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initialXNone  Time frame: pasXNone	Specifications/Comments (e.g., if payments were made to you or to your institution)  al planning of the work

Consulting fees

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	ease summarize the above c	onflict of interest in the fo	lowing box:

Da	te:2023/03	3/17		
Yo	ur Name: Ren	chang Zhao		
Ma	anuscript Title: Cyclin	O promotes lung cance	er progression and cetuximab resistance via cell cycl	e
	gulation and CDK13 inte			
Ma	anuscript number (if known	):		
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.	
	e following questions apply nuscript only.	to the author's relationsh	nips/activities/interests as they relate to the current	
to	•	ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertain e all relationships with manufacturers of antihypertensive the manuscript.	
	item #1 below, report all su e time frame for disclosure i	• •	ed in this manuscript without time limit. For all other iten	ıs,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initi	al planning of the work	
L	All support for the present manuscript (e.g., funding, provision of study materials,	XNone		
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: pas	st 36 months	
<u> </u>	Grants or contracts from	XNone		
	any entity (if not indicated in item #1 above).		<u> </u>	
2	Royalties or licenses	X None		
,	Noyalties of ficelises			

Consulting fees

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
O	pending	XNOTIC	
	pending		
9	Participation on a Data	X None	
9	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
	None		

Da	te:2023/03	3/17	
Yo	ur Name:Zito	ng Feng	
Ma	anuscript Title: Cyclin	O promotes lung cance	er progression and cetuximab resistance via cell cycle
	gulation and <i>CDK13</i> inte		
Ma	anuscript number (if known)	):	
rel pa to rel Th ma Th to me	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, be following questions apply anuscript only.  The author's relationships/act the epidemiology of hypertedication, even if that medicatem #1 below, report all su	manuscript. "Related" mee affected by the content necessarily indicate a bias it is preferable that you do to the author's relationshivities/interests should be ension, you should declaration is not mentioned in pport for the work report	nips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive
the	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)
		none (add rows as needed)	
		Time frame: Since the initia	al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		1	
		Time frame: pag	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas	st 36 months
3	any entity (if not indicated		st 36 months
3	any entity (if not indicated in item #1 above).	XNone	st 36 months

Consulting fees

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	XNone	
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical	X None	
12			
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
	ease summarize the above c	onflict of interest in the fo	llowing box:

Dat	:e:2023/03	/17	
Υοι	ur Name: Jian	g Wang	
Ма	nuscript Title: Cyclin	O promotes lung cance	er progression and cetuximab resistance via cell cycle
	gulation and <i>CDK13</i> inte		•
_	nuscript number (if known)		
rela par to t rela The ma The to t me	ated to the content of your ties whose interests may be cransparency and does not extionship/activity/interest, a following questions apply nuscript only.  The author's relationships/activity endication, even if that medication, even if that medication.	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you do to the author's relationsh ivities/interests should be ension, you should declare eation is not mentioned in	ips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initia	al planning of the work
	All of the	1	ai pianning of the work
L	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
,	in item #1 above).	V None	
)	Royalties or licenses	XNone	
1	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone		
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
_				
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
4 -	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
-1	Stock of Stock options			
12	Receipt of equipment,	X None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
<b>-</b> :		Clara . Clara	H L.	
Ple	Please summarize the above conflict of interest in the following box:			
	None			

Da	te:2023/03	3/17		
	ur Name: Hui			
Ma	anuscript Title: Cyclin	O promotes lung cance	er progression and cetuximab resistance via cell cy	cle
re	gulation and <i>CDK13</i> inte	raction		
Ma	anuscript number (if known)	:		
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.	
	e following questions apply anuscript only.	to the author's relationsh	nips/activities/interests as they relate to the current	
to	•	ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript perta e all relationships with manufacturers of antihypertension the manuscript.	
	item #1 below, report all su e time frame for disclosure i	•	ed in this manuscript without time limit. For all other it	ems,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as needed)		
		Time frame: Since the initi	al planning of the work	
	All support for the present	X None	ar praiming or the front	
-	manuscript (e.g., funding,	XNone		
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame, no	at 26 months	
)	Grants or contracts from	Time frame: pas X None	St 50 Holldis	
-	any entity (if not indicated			
	in item #1 above).			
}	Royalties or licenses	XNone		

Consulting fees

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XNone	
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	10 Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
	ease summarize the above o	onflict of interest in the fo	llowing box: